Why Medtronic Stock Marched Higher on Monday
Medtronic (NYSE: MDT) stock was a fairly hot item as the trading week kicked off, with investors pushing the shares up by almost 3% in value. They liked the medical device specialist's latest piece of news about one of its products, and reacted accordingly. The stock's gain easily topped that of the S&P 500 (SNPINDEX: ^GSPC), which closed the day up 0.6%. On Sunday, Medtronic published five-year data from a low-risk clinical trial of its Evolut transcatheter aortic valve replacement (TAVR) system. In the trial, TAVR, which assists patients suffering from the heart valve disorder aortic stenosis, was tested against surgical aortic vale replacement (SAVR). The trial's participants all had severe forms of the disorder. TAVR was shown to have comparable rates of all-cause mortality or disabling stroke. Continue reading
Medtronic (NYSE: MDT) stock was a fairly hot item as the trading week kicked off, with investors pushing the shares up by almost 3% in value. They liked the medical device specialist's latest piece of news about one of its products, and reacted accordingly. The stock's gain easily topped that of the S&P 500 (SNPINDEX: ^GSPC), which closed the day up 0.6%.
On Sunday, Medtronic published five-year data from a low-risk clinical trial of its Evolut transcatheter aortic valve replacement (TAVR) system.
In the trial, TAVR, which assists patients suffering from the heart valve disorder aortic stenosis, was tested against surgical aortic vale replacement (SAVR). The trial's participants all had severe forms of the disorder. TAVR was shown to have comparable rates of all-cause mortality or disabling stroke.
